Published in Haematologica on January 22, 2012
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood (2014) 1.54
On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure. J Cardiovasc Magn Reson (2011) 1.05
Treating thalassemia major-related iron overload: the role of deferiprone. J Blood Med (2012) 0.92
Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol Dis (2012) 0.90
Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion. Rev Bras Hematol Hemoter (2013) 0.86
Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. J Cardiovasc Magn Reson (2011) 0.82
Deferasirox: appraisal of safety and efficacy in long-term therapy. J Blood Med (2013) 0.80
Longitudinal monitoring of cardiac siderosis using cardiovascular magnetic resonance T2* in patients with thalassemia major on various chelation regimens: a 6-year study. Am J Hematol (2013) 0.78
Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions. Ther Clin Risk Manag (2016) 0.78
Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. J Blood Med (2015) 0.78
The long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan. Ann Hematol (2015) 0.78
Impact of cardiac magnetic resonance imaging in non-ischemic cardiomyopathies. World J Cardiol (2016) 0.77
Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. Blood (2015) 0.77
Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats. PLoS One (2016) 0.76
MRI Measurements of Iron Load in Transfusion-Dependent Patients: Implementation, Challenges, and Pitfalls. Pediatr Blood Cancer (2015) 0.75
Validation of a new t2* algorithm and its uncertainty value for cardiac and liver iron load determination from MRI magnitude images. Magn Reson Med (2015) 0.75
Evaluation of Iron Deposition in the Adrenal Glands of β Thalassemia Major Patients Using 3-Tesla MRI. Iran J Radiol (2016) 0.75
Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02
Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med (2006) 32.81
Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J (2001) 8.90
Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet (2002) 6.11
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood (2005) 6.07
Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med (1994) 5.32
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica (2004) 5.21
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation (2007) 2.93
Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation (2009) 2.85
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood (2005) 2.75
Survival and causes of death in thalassaemia major. Lancet (1989) 2.72
Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol (2004) 2.59
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood (2005) 2.45
On T2* magnetic resonance and cardiac iron. Circulation (2011) 2.33
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood (2009) 2.20
Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica (2003) 2.17
Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson (2008) 1.76
The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood (2010) 1.41
Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Blood (2008) 1.24
Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. Eur J Haematol (2006) 1.21
Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica (2010) 1.19
On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure. J Cardiovasc Magn Reson (2011) 1.05
Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica (2010) 1.04
Relation of myocardial T2* to right ventricular function in thalassaemia major. Eur Heart J (2010) 0.97
Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial. Am J Hematol (2010) 0.84
Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit. Eur J Haematol (2010) 0.84
Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. Eur J Haematol (2010) 0.83
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood (2005) 6.07
Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol (2006) 5.58
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica (2004) 5.21
ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner. Cell (2010) 4.34
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet (2007) 3.94
Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med (2015) 3.25
Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica (2005) 2.64
Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol (2004) 2.59
A regulatory SNP causes a human genetic disease by creating a new transcriptional promoter. Science (2006) 2.58
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica (2006) 2.54
Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster. Blood (2009) 2.50
Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood (2005) 2.45
On T2* magnetic resonance and cardiac iron. Circulation (2011) 2.33
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol (2012) 2.29
Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost (2006) 2.27
A severe alpha thalassemia case compound heterozygous for Hb Adana in alpha1 gene and 20.5 kb double gene deletion. J Pediatr Hematol Oncol (2009) 2.21
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood (2009) 2.20
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood (2005) 2.02
Should all children admitted with community acquired pneumonia have blood cultures taken? Indian J Pediatr (2014) 2.01
In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. Blood (2005) 1.96
A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis (2002) 1.89
Disseminated cryptosporidium infection in an infant with hyper-IgM syndrome caused by CD40 deficiency. J Pediatr (2003) 1.84
Human metapneumovirus detection in patients with severe acute respiratory syndrome. Emerg Infect Dis (2003) 1.81
Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood (2007) 1.78
A genome-wide association identified the common genetic variants influence disease severity in beta0-thalassemia/hemoglobin E. Hum Genet (2010) 1.75
Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol (2007) 1.74
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica (2009) 1.73
Frameshift mutation in p53 regulator RPL26 is associated with multiple physical abnormalities and a specific pre-ribosomal RNA processing defect in diamond-blackfan anemia. Hum Mutat (2012) 1.64
Nonhematopoietically derived DNA is shorter than hematopoietically derived DNA in plasma: a transplantation model. Clin Chem (2011) 1.63
Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol (2013) 1.62
Iron overload in the Asian community. Blood (2009) 1.59
Total white blood cell count is associated with the presence, severity and extent of coronary atherosclerosis detected by dual-source multislice computed tomographic coronary angiography. Cardiol J (2011) 1.59
Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica (2008) 1.54
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood (2014) 1.54
Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia. Biol Blood Marrow Transplant (2010) 1.53
Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years. Gastroenterology (2011) 1.51
Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood (2009) 1.50
A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood (2012) 1.49
Presence of donor-derived DNA and cells in the urine of sex-mismatched hematopoietic stem cell transplant recipients: implication for the transrenal hypothesis. Clin Chem (2008) 1.45
Optimal management of β thalassaemia intermedia. Br J Haematol (2011) 1.41
Laboratory diagnosis of SARS. Emerg Infect Dis (2004) 1.41
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol (2009) 1.40
Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet (2003) 1.40
Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. Br J Haematol (2014) 1.40
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica (2012) 1.35
Adventitious changes in long-range gene expression caused by polymorphic structural variation and promoter competition. Proc Natl Acad Sci U S A (2009) 1.35
Paediatric cancer in low-income and middle-income countries. Lancet Oncol (2013) 1.35
Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. J Magn Reson Imaging (2007) 1.34
Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood (2004) 1.34
Thrombosis and sickle cell disease. Semin Thromb Hemost (2011) 1.32
Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica (2004) 1.30
How I treat transfusional iron overload. Blood (2012) 1.29
White matter and cerebral metabolite changes in children undergoing treatment for acute lymphoblastic leukemia: longitudinal study with MR imaging and 1H MR spectroscopy. Radiology (2003) 1.28
Psychosocial aspects and psychiatric disorders in young adult with thalassemia major. Intern Emerg Med (2008) 1.27
Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol (2003) 1.23
Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica (2011) 1.23
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol (2009) 1.23
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. Leuk Res (2010) 1.23